Dienogest: an oral progestogen for the treatment of endometriosis. (January 2011)

• Record Type: Journal Article
• Authors: Mueck, Alfred O
• Is Part Of: Expert review of obstetrics & gynecology. Volume 6:Number 1(2011)
• Page Start: 5
• Page End: 15
• Publication Date: 2011-01
• Subjects: dienogest -- endometrial pain -- endometriosis -- endometriotic lesions -- oral progestogen; Obstetrics -- Periodicals; Gynecology -- Periodicals; 618.05
• DOI: 10.1586/eog.10.71
• Languages: English
• ISSNs: 1747-4108

Abstract

Dienogest is a progestogen that combines the pharmacological properties of 19-norprogestins and progesterone derivatives. Dienogest has a potent effect on endometrial tissue, producing antiproliferative effects on endometriotic cells, as well as anti-inflammatory and antiangiogenic actions. Dienogest has been systematically investigated for the treatment of endometriosis through comprehensive study programs in Europe and Japan. Clinical experience of dienogest at 2 mg daily orally demonstrates that it significantly reduces endometriotic lesions and provides effective pain relief comparable to the current efficacy standard, combined with a favorable safety and tolerability profile that allows long-term use. Study data over 15 months show sustained pain relief and low incidences of treatment-related adverse events. As with other progestogens, spotting or breakthrough bleeds are common, but usually lessen during long-term treatment. Dienogest does not produce antiestrogenic side effects, such as bone mass loss. This article reviews the evidence for the use of dienogest in endometriosis.